DMPK Strategies in the Preclinical Development of Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) stand out as innovative biotherapeutics, composed of cytotoxic payloads conjugated to antibodies through chemical linkers. ADCs present a complex landscape for understanding their ADME (adsorption, distribution, metabolism, and excretion) properties during the discovery and development stages. The efficacy of ADCs depends on the precise release and concentration of the payload in target tissues, while minimizing toxicity requires preventing off-target release in non-target tissues. Navigating this complexity demands a dual approach, integrating small molecule bioanalysis and large molecule bioanalysis platforms for comprehensive pharmacokinetic studies.

Our webinar, "DMPK Strategies in the Development of Antibody-Drug Conjugates," is designed to provide you with a strategic pharmacokinetic study plan tailored to the diverse structures of ADC projects. Throughout the webinar, we will cover challenging yet essential aspects of investigating ADCs such as payload release, catabolite identification in multiple in vitro systems, drug–antibody ratio (DAR) detection, and integrated bioanalysis platform for both small and large molecules.